DNMT1 and cancer: By inhibiting epigenetic regulators like LSD1, EZH2, HDAC, and DNMT, cancer cells can enhance the expression of certain molecules that facilitate the activation of immune responses, thus rendering them more amenable to immunotherapy [244].